Ceribell (CBLL) Merges Rapid and Conventional EEG Into One System

On its FY2026 second-quarter earnings call on August 10, 2026, Ceribell, Inc. (CBLL) described a new EEG hardware platform whose components have received FDA 510(k) clearance, and management said the combination now delivers "almost all the functionality of the conventional EEG" [1]. Ceribell is the only company on the record about this change, and it has placed the revenue contribution in 2027; the 2026 guidance range excludes it [1].

---

Why hospitals have had to buy two separate EEG systems

An EEG records the brain's electrical activity through electrodes placed on the scalp. When an intensive care unit suspects a patient is having a seizure, clinicians need to know quickly whether abnormal electrical activity is present. The conventional route is slow: a cart-based EEG machine is wheeled in, a technician places more than twenty electrodes across the scalp to a standard layout, and a neurologist then reads the recording and issues a formal report. Ceribell sells something different — a headband with very few electrodes that a nurse can put on in a few minutes, with an algorithm that flags seizure activity directly. The speed comes at a cost: a reduced-electrode headband cannot produce that formal report, so hospitals buy both, from two different vendors.

The hardware itself is what changed. Ceribell says it has obtained FDA 510(k) clearances for the components of its new platform, including a recorder that accepts video and ECG and can record continuously for days, a full-montage add-on covering the parasagittal region (either side of the midline at the top of the head), and headbands rated for multi-day wear [1]. The add-on does not work on its own — it pairs with the company's existing headband and plugs into the same recorder to produce a formal study [1]. The category line that electrode count used to draw has now been crossed by one company's product line.

---

Management puts the payoff in 2027

The Q&A set out what the new recorder does. According to CEO Jane Chao, it takes a video feed and a larger screen, monitors continuously for days or even weeks, and integrates ECG and other vital signs into the recording; the company's existing seizure algorithm, its delirium algorithm (delirium is an acute confusional state common in intensive care) and future algorithms all run on that one device [1]. She then named the category shift directly [1].

Guidance on the same call marks off what has not yet arrived. CFO Scott Blumberg guided FY2026 revenue to $114–117 million, up from a prior $112–116 million, representing 28–31% annual growth over 2025, and said the range does not include material contributions from the neonate, pediatric or delirium products, which the company expects to translate into revenue more meaningfully in 2027 [1].

The prior call dates the shift. On the FY2026 first-quarter call of May 11, 2026, management's montage commentary was about the existing headband — its layout is consistent with the American Clinical Neurophysiology Society (ACNS) guideline for the full montage, and pediatric epileptologists were supportive because they could see the full picture [2]. No next-generation hardware platform appeared anywhere on that call [2].

---

What merging two purchases into one does to the buying entry point

One device that covers both rapid screening and the formal study collapses two hospital purchases into one, and that purchase is more likely to sit with whichever vendor reaches the patient first. A headband a nurse can apply in minutes enters the ward workflow earlier, while a cart that requires a technician to come and wire the patient rarely makes it to the bedside in the emergency department or intensive care unit at that moment. The entry point moves closer to the step a nurse can complete alone, and the ability to produce a formal report shifts from a criterion for picking a vendor to one option inside a single system.

The boundary around that inference is clear. The new platform has not launched, the company itself places the revenue contribution in 2027, and the 2026 guidance does not include it [1]. Whether hospitals will actually replace two vendors with one is not addressed by any hospital or competitor in the research record. The side being absorbed is also close to unverifiable: Natus Medical is private under ArchiMed, Cadwell Industries is private, and Compumedics is listed in Australia. What can be tracked from here is whether the new hardware platform launches on schedule in 2027 and whether the company begins to disclose revenue for the new categories separately.

---

Companies exposed to this change

• Nihon Kohden (6849.T): One of the main suppliers of conventional cart-based diagnostic EEG equipment, and on the side that could be absorbed; if a single system handles both rapid screening and the formal study, the need to buy a cart-based EEG separately declines. The company has made no disclosure of its own on this.
• Masimo (MASI): Sells bedside patient monitoring equipment for intensive care, with brain function monitoring as an adjacent category; once rapid EEG becomes a brain monitor that can be worn continuously for days, the two would appear on the same bedside monitoring purchase list. This exposure rests on category adjacency alone, with no statement from the company itself.

---

Sources

[1] Drillr · Ceribell, Inc. (CBLL) · 2026-08-10 · FY2026 Q2 earnings call

with this entire new hardware, we're not just the brain monitor anymore. We also provide almost all the functionality of the conventional EEG.

[2] Drillr · Ceribell, Inc. (CBLL) · 2026-05-11 · FY2026 Q1 earnings call

---

This is only meant to surface industry changes and companies you may have overlooked - it is not a stock recommendation.